Key result
Routine once-in-a-lifetime Lp(a) testing identifies elevated cardiovascular risk in ~20% of adults.
Why the study?
Lipoprotein(a) is elevated in an estimated 20% to 25% of people, yet it remains an underrecognized risk factor for atherosclerotic heart disease and calcific aortic valve disease in primary care.
Highlights the recommendation for universal one-time lipoprotein(a) screening in adults to identify and manage the 20%–25% of individuals with elevated levels in primary care.
Answers are grounded in this paper and cite their sources.
Supports one-time lipoprotein(a) measurement for adult risk assessment; leaves open outcome impact pending randomized trials.
In the US, cardiovascular disease is the leading cause of death for men and women of most racial and ethnic groups. An estimated 20%–25% of people have elevated lipoprotein(a) [Lp(a)] levels; however, it is an underrecognized risk factor for atherosclerotic heart disease and calcific aortic valve disease. Lp(a) levels are genetically determined and unaffected by lifestyle modifications and statin therapy. It is recommended that Lp(a) be measured in all adults at least once for risk assessment. Primary care nurse practitioners are well positioned to perform risk stratification, provide patient education, and manage elevated Lp(a) levels.
No takes yet. Share an insight, caveat, or question.
Susan D. Hellier (2026) conducted a review in Cardiovascular disease / elevated lipoprotein(a) [Lp(a)]. Lipoprotein(a) [Lp(a)] measurement and risk stratification was evaluated on Atherosclerotic heart disease and calcific aortic valve disease risk assessment. Elevated lipoprotein(a) affects an estimated 20%-25% of people and is recommended to be measured at least once in all adults to assess cardiovascular risk.
Synapse has enriched 10 related papers. Consider them for comparative context: